|
Roche recognised as new Super Sector Leader in Dow Jones Sustainability Index
|
04 September 2009 |
|
Avastin approved in US for the most common type of kidney cancer
|
03 August 2009 |
|
Xeloda in combination with oxaliplatin shown to be effective in early colon cancer
|
22 July 2009 |
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
|
06 July 2009 |
|
Roche announces new two-year data from the LITHE study
|
26 May 2009 |
|
Roche provides additional donation of 5.65 million packs of Tamiflu to WHO
|
14 May 2009 |
|
Roche strongly outperforms market in first quarter
|
22 April 2009 |
|
Roche Diabetes Care supports "Changing Diabetes in Children"
|
16 April 2009 |
|
Roche acquires innovatis AG to complement its product portfolio
|
17 March 2009 |
|
Roche Annual General Meeting: dividend raised by 9 percent
|
11 March 2009 |
|
Roche increases offer price for Genentech shares to US$ 93 per share
|
09 March 2009 |
|
Immune-boosting effect of Pegasys provides patients with the chance for a clinical cure
|
17 February 2009 |
|
Strong operating results for Roche in 2008
|
06 February 2009 |
|
Roche Announces Interim Results from a Phase III ATLAS Study
|
03 February 2009 |
|
Foundation-laying ceremony for new R&D building at Roche Basel
|
24 January 2009 |
|
Roche and Axiogenesis Enter into Co-Development and Marketing Agreement
|
10 December 2008 |
|
Roche signs definitive agreement to acquire Memory Pharmaceuticals
|
01 December 2008 |
|
Tarceva brings new hope to patients with advanced non-small cell lung cancer
|
12 November 2008 |
|
Roche posts sustained double-digit sales growth for the first nine months of 2008
|
25 October 2008 |
|
Roche invests 215 million Swiss francs in diagnostics facility at Penzberg
|
02 October 2008 |